Unknown

Dataset Information

0

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.


ABSTRACT: Abnormal hepatic insulin signaling is a cause or consequence of hepatic steatosis. DPP-4 inhibitors might be protective against fatty liver. We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice. In the present study, we investigated the effects of a DPP-4 inhibitor, linagliptin, on hepatic steatosis in OSI-906-treated mice. Unlike high-fat diet-induced hepatic steatosis, OSI-906-induced hepatic steatosis is not characterized by elevations in inflammatory responses or oxidative stress levels. Linagliptin improved OSI-906-induced hepatic steatosis via an insulin-signaling-independent pathway, without altering glucose levels, free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy. Hepatic quantitative proteomic and phosphoproteomic analyses revealed that perilipin-2 (PLIN2), major urinary protein 20 (MUP20), cytochrome P450 2b10 (CYP2B10), and nicotinamide N-methyltransferase (NNMT) are possibly involved in the process of the amelioration of hepatic steatosis by linagliptin. Thus, linagliptin improved hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation, suggesting the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions.

SUBMITTER: Okuyama T 

PROVIDER: S-EPMC7672621 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.

Okuyama Tomoko T   Shirakawa Jun J   Tajima Kazuki K   Ino Yoko Y   Vethe Heidrun H   Togashi Yu Y   Kyohara Mayu M   Inoue Ryota R   Miyashita Daisuke D   Li Jinghe J   Goto Nozomi N   Ichikawa Taiga T   Yamasaki Shingo S   Ohnuma Haruka H   Takayanagi Rie R   Kimura Yayoi Y   Hirano Hisashi H   Terauchi Yasuo Y  

International journal of molecular sciences 20201022 21


Abnormal hepatic insulin signaling is a cause or consequence of hepatic steatosis. DPP-4 inhibitors might be protective against fatty liver. We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice. In the present study, we investigated the effects of a DPP-4 inhibitor, linagliptin, on hepatic steatosis in  ...[more]

Similar Datasets

| S-EPMC5466328 | biostudies-literature
2020-01-30 | GSE132056 | GEO
| S-EPMC5323884 | biostudies-literature
| S-EPMC6116094 | biostudies-literature
| S-EPMC7031743 | biostudies-literature
| S-EPMC7251170 | biostudies-literature
| S-EPMC6398497 | biostudies-literature
| S-EPMC6545697 | biostudies-literature
| S-EPMC2645992 | biostudies-other
| S-EPMC2014135 | biostudies-other